Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

• CAR T cell therapy effectively controls myeloma even when BCMA expression is limited, indicating resilience.
• Key evidence includes observation of antigen expression on different target cell lines demonstrating variability.
• The approach involves an analysis of immune responses against distinct target cell lines expressing BCMA and CD229 antigens.
• Implications of these findings suggest potential for broader application in cases with limited BCMA expression.